The effects of synthetic conjugated estrogens, a (Cenestin) on trabecular bone structure and strength in the ovariectomized rat model

Osteoporosis International

Volumn 13, Issue 10, 2002, Pages 816-823

  Lane, Nancy E ^a,c   Kumer, J L ^a   Majumdar, S ^a   Khan, M ^a   Lotz, J ^a   Stevens, R E ^b   Klein, R ^b   Phelps, K V ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Duramed Pharmaceuticals Inc   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Ovariectomized rats; Synthetic conjugated estrogens; Trabecular bone structure and strength

Indexed keywords

CONJUGATED ESTROGEN; DEOXYPYRIDINOLINE; OSTEOCALCIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD LEVEL; BONE STRENGTH; BONE STRUCTURE; BONE TURNOVER; COMPRESSION; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FRACTURE; NONHUMAN; OVARIECTOMY; PRIORITY JOURNAL; RAT; TIBIA; TRABECULAR BONE; URINE LEVEL;

ANIMALS; BONE AND BONES; BONE DENSITY; BONE REMODELING; ESTRADIOL CONGENERS; ESTROGENS, CONJUGATED (USP); FEMALE; MODELS, ANIMAL; OVARIECTOMY; RANDOM ALLOCATION; RATS; RATS, SPRAGUE-DAWLEY;

EID: 0036820570     PISSN: 0937941X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s001980200113     Document Type: Article

References (39)

1. Cummings SR, Kelsey JL, Nevitt MC, et al. Epidemiology of osteoporosis and osteoporotic fractures. Epidemiol Rev 1991;7:178-208.
2. Buillion R, Burkhardt P, Christiansen C, et al. Consensus development conference: prophylaxis and treatment of osteoporosis. Osteoporos Int 1991;1:114-7.
3. Lane NE, Haupt D, Kimmel DB, et al. Early estrogen treatment replacement therapy reverses the rapid loss of trabecular bone volume and prevents further deterioration of connectivity in the rat. J Bone Miner Res 1999;14:206-12.
4. Lufkin EG, Wahner HW, O'Fallon WM, et al. Treatment of postmenopausal osteoporosis with transdermal estrogen. Ann Intern Med 1992;117:1-9.
5. Lindsay R, Hart DM, Clark DM. The minimal effective dose of estrogen for prevention of postmenopausal bone loss. Obstet Gynecol 1984;63:759-64.
6. Garnero P, Stevens RE, Ayres SA, et al. Short-term effects of a new synthetic conjugated estrogens on biochemical markers of bone turnover. American Society for Bone and Mineral Research, 22nd Annual Meeting, Toronto, Ontario, Canada, Sept. 22-26, 2000.
7. Duramed Pharmaceuticals Inc. Cenestin product monograph. Cincinnati, OH: Duramed, July 2000.
8. Fieser LF, Fieser M. Steroids. New York: Reingold, 1959:547-55.
9. Draper CR, Edel MJ, Dick M, et al. Phytoestrogens reduce bone loss and bone resorption in oopherectomized rats. J Nutr 1996;127:1795-9.
10. Arjmandi BH, Alekel L, Hollis BW, et al. Dietary soybean protein prevents bone loss in an ovariectomized rat model of osteoporosis. J Nutr 1996;126:161-7.
11. Fanti P, Monier-Faugere MC, Geng Z, et al. The phytoestrogen genistein reduces bone loss in short-term ovariectomized rats. Osteoporos Int 1998;8:274-81.
12. Wronski TJ, Cintron M, Doherty AL, Dann LM. Estrogen treatment prevents osteopenia and depresses bone turnover in ovariectomized rats. Endocrinology 1988;123:681-6.
13. Waynforth HB. Experimental and surgical techniques in the rat. New York: Academic Press, 1980.
14. Lane NE, Haupt D, Modin G, et al. The acute change in trabecular bone connectivity and osteoclast activity in a rat model of estrogen deficiency. J Bone Miner Res 1998;13:229-36.
15. Freireich EJ, Gehan EA, Rall DP, et al. Quantitative comparison of toxicity of anti-cancer agents in mouse, rat, dog, monkey and man. Cancer Chemother Rep 1966;50:219-44.
16. Laib A, Kumer JL, Majumdar S, et al. The temporal changes in trabecular architecture in ovariectomized rats assessed by microCT. Osteoporos Int 2001;12:936-41.
17. Laib A, Barou O, Vico L, et al. 3D micro-computed tomography of trabecular and cortical bone architecture with application to a rat model of immobilization osteoporosis. Med Biol Eng Comput 2000;38:326-32.
18. Hildebrand T, Rüegsegger P. A new method for the model independent assessment of thickness in three-dimensional images. J Microsc 1997;85:67-75.
19. Lorensen WE, Cline HE. Marching cubes: a high-resolution 3D surface construction algorithm. Comput Graph 1987;21:163-9.
20. Hildebrand T, Rüegsegger P. Quantification of bone micro-architecture with the structure model index. Comput Methods Biomech Biomed Eng 1997;1:15-23.
21. Adams DJ, Diaz-Doran V. Resolution sensitivity and precision of mouse trabecular bone morphometry measurements by micro- computed tomographic imaging. J Bone Miner Res 2001;16 (Suppl 1):S345.
22. Lotz J, Kroeber MW, Heilmann M, et al. Tibial plateau fracture is a sensitive measure of estrogen-dependent bone fragility. J Orthop Res 2000;18:326-32.
23. Balena R, Markatos A, Seedor JG, et al. The effects of 2-year treatment with the aminobisphosphonate alendronate on bone metabolism, bone histomorphometry, and bone strength in ovariectomized nonhuman primates. J Clin Invest 1993;92:2577-86.
24. Sokal R, Rohlf FJ. Biometry. San Francisco: Freeman, 1969.
25. Li X, Takahashi M, Kushida K, et al. The preventive and interventional effects of raloxifene analog (LY117018HCL) on osteopenia in ovariectomized rats. J Bone Miner Res 1998;13:5-10.
26. Frolik CA, Bryand HU, Black EC, et al. Time-dependent changes in biochemical bone markers and serum cholesterol in ovariectomized rats: Effects of raloxifene HCl, tamoxifene, estrogen, alendronate. Bone 1996;18:621-7.
27. Muller K, Wiesenberg I, Jaeggi K, et al. Effects of the bisphosphonate zoledronate on bone loss in the ovariectomized rat and in adjuvant arthritis. Arzneimittel-Forsch 1998;48:81-6.
28. Thompson DD, Seedor JG, Quartuccio H, et al. The bisphosphonate, alendronate, prevents bone loss in ovariectomized baboons. J Bone Miner Res 1992;7:951-60.
29. Rodan GA, Seedor JG, Balena R. Preclinical pharmacology of alendronate. Osteoporos Int 1993;4(Suppl 3):S7-12.
30. Boyce RW, Wronski TJ, Ebert DC, et al. Direct sterological estimation of three-dimensional connectivity in rat vertebrae: effect of estrogen, etidronate and risedronate following ovariectomy. Bone 1995;16:209-13.
31. Lane NE, Thompson JM, Strewler GJ, et al. Intermittent treatment with human parathyroid hormone (hPTH 1-34) increased trabecular bone volume but not connectivity in osteopenic rats. J Bone Miner Res 1995;10:1470-7.
32. Cummings SR, Black D, Karpt DE. Improvement in spine bone mineral density and reduction in risk of vertebral fractures during treatment with anti-resorptive drugs. Am J Med 2002;114:281-9.
33. Black DB, Cummings SR, Karpt DB, et al. Randomized trial of the effect of alendronate on risk of fracture in women with existing vertebral fractures. Lancet 1996;348:1535-41.
34. Hochberg M. Preventing fractures in postmenopausal women with osteoporosis: a review of recent controlled trials of antiresorptive agents. Drugs Aging 2000;17:317-30.
35. Kroeber MW, Lotz JC, Heilmann M, et al. Estrogen treatment maintains strength of rat bones after ovariectomy. Trans Orthop Res Soc 1999.
36. Chavassieux PM, Arlot ME, Reda C, et al. Histomorphometric assessment of the long-term effects of alendronate on bone quality and remodeling in patients with osteoporosis. J Clin Invest 1997;100:1475-80.
37. Agnusdei D, Gennari C, Bufalino, L. Prevention of early postmenopausal bone loss using low doses of conjugated estrogens and the non-hormonal, bone-active drug ipriflavone. Osteoporos Int 1995;5:462-6.
38. Agnusdei D, Bufalino L. Efficacy of ipriflavone in established osteoporosis and long-term safety. Calcif Tissue Int 1997;61 (Suppl 1):S23-7.
39. Ishimi Y, Miyaura C, Ohmura M, et al. Selective effects of genisten, a soybean isoflavone, on B-lymphopoiesis and bone loss caused by estrogen deficiency. Endocrinology 1999;140:898-900.